Printer Friendly

IMMUNOMEDICS REPORTS NEW CLINICAL RESULTS OF INFECTIOUS DISEASE IMAGING AGENT

 IMMUNOMEDICS REPORTS NEW CLINICAL RESULTS OF INFECTIOUS
 DISEASE IMAGING AGENT
 WARREN, N.J., March 16 /PRNewswire/ -- Immunomedics, Inc. (NASDAQ: IMMU), reported today new Phase I/II clinical trial results describing the potential usefulness of the company's infectious disease imaging agent, ImmuRAID(TM)-MN3, in detecting osteomyelitis (bone infection) and infections in prosthetic joints, at the Cowen & Company Health Care Industry Conference in Boston. Seventeen patients have been enrolled in this Phase I/II clinical trial program being conducted in the United States and Europe.
 ImmuRAID-MN3 consists of a white blood cell-targeting monoclonal antibody fragment directly labeled with the low-cost, widely available radioisotope, technetium-99m, in a simple, rapid, one-step procedure. The company plans to advance ImmuRAID-MN3 to worldwide multicenter Phase III clinical trials within six months.
 David Goldenberg, chairman, presented case studies in which ImmuRAID-MN3 detected osteomyelitis in the foot of a diabetic patient and an infection in a patient's hip prosthesis. In both of these cases ImmuRAID-MN3 revealed infections more rapidly and more definitively than Indium-111 white blood cell scanning, which is the current test being used.
 "Improving the detection of a suspected yet undisclosed infection enables physicians to select the most appropriate therapy. ImmuRAID-MN3 provides images within one to four hours after injection and, in contrast to an Indium-111 white blood cell scan, ImmuRAID-MN3 does not involve handling a patient's blood, reducing health risks to medical personnel," stated Goldenberg.
 Immunomedics is a biopharmaceutical company applying innovative technology in antibody selection, modification and chemistry to the development of products for the detection and treatment of cancers and infectious diseases. Integral to these products are highly specific monoclonal antibodies designed to deliver radioisotopes, chemotherapeutic agents or toxins to tumors and sites of infections.
 -0- 3/16/92
 /CONTACT: Amy Factor of Immunomedics, 908-647-5400/
 (IMMU) CO: Immunomedics, Inc. ST: New Jersey IN: MTC SU:


GK-OS -- NY064 -- 8398 03/16/92 15:06 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 16, 1992
Words:311
Previous Article:USAIR EXPRESS TO EXPAND SERVICE AT CHARLOTTESVILLE, REPLACE USAIR JET SERVICE TO CHARLOTTE
Next Article:AAMES FINANCIAL OPENS 19TH BRANCH OFFICE TO SERVE CONSUMERS IN CALIFORNIA
Topics:


Related Articles
IMMUNOMEDICS REPORTS RESULTS OF NEW CANCER THERAPEUTIC
GERMAN STUDY SHOWS PROMISING RESULTS FOR IMMUNOMEDICS' INFECTIOUS DISEASE IMAGING AGENT
IMMUNOMEDICS REPORTS VIRTUALLY NO ALLERGIC REACTIONS IN PATIENTS IMAGED WITH ANTIBODY AGENT, IMMURAID-CEA
IMMUNOMEDICS ANNOUNCES POSITIVE CLINICAL RESULTS
IMMUNOMEDICS RECEIVES FDA APPROVABLE LETTER FOR CEA-SCAN
IMMUNOMEDICS AWARDED ORPHAN DRUG DESIGNATION FOR CEA-SCAN IN THE DIAGNOSIS OF MEDULLARY THYROID CANCER
IMMUNOMEDICS' RADIOLABELED ANTIBODY SHOWS ACTIVITY IN OVARIAN CANCER
IMMUNOMEDICS IS GRANTED TWO U.S. PATENTS
IMMUNOMEDICS COMPLETES NEW MANUFACTURING FACILITY; ALSO DEVELOPS MORE EFFICIENT MANUFACTURING PROCESS
Immunomedics Patents New Diagnostic and Therapeutic Agents

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters